Key result
Anti-FXa assays incorporating low molecular weight dextran sulfate and utilizing CTAD anticoagulant optimize the accurate measurement of all in-vivo heparin activity.
Why the study?
External quality assessment surveys still report high inter-assay variability for anti-FXa assays despite WHO international standards, driven by assay formulation, calibrators, and automation parameters.
Does the addition of dextran sulfate and use of CTAD anticoagulant improve the accuracy of anti-FXa assays for measuring heparin activity?
Does the addition of dextran sulfate and use of CTAD anticoagulant improve the accuracy of anti-FXa assays for measuring heparin activity?
Optimizing anti-FXa assays with dextran sulfate and CTAD anticoagulant improves the accuracy of heparin monitoring by mobilizing all drug present in blood circulation.
Answers are grounded in this paper and cite their sources.
May refine heparin monitoring in labs; hypothesis-generating and requires prospective validation before any practice change.
Heparins, Unfractionated or Low Molecular Weight, are permanently at the spotlight of both clinical indications and laboratory monitoring. An accurate drug dosage is necessary for an effi-cient and safe therapy. The one-stage anti-FXa kinetics’ assays are the most widely and universally used with full automation for large series, without needing exogenous Antithrombin. WHO in-ternational standards are available for UFH and LMWH, but external quality assessment surveys still report a high inter-assay variability. This heterogeneity results from: assay formulation, designed without or with dextran sulfate to measure all heparin in blood circulation; calibrators for testing UFH or LMWH with the same curve; and automation parameters. The various factors which impact heparin measurements are reviewed, and we share our experience to optimize assays for completely testing plasma heparin. Evidence is provided on the usefulness of low molecular weight dextran sulfate to mobilize all drug present in blood circulation. Other key factors concern adjustment of assay conditions to obtain fully superimposable calibration curves for UFH and LMWH, and automation parameters. The study is illustrated by the performances of the various anti-FXa assays used for testing heparin on UFH or LMWH treated patients’ plasmas and obtained using citrate or CTAD anticoagulants. Comparable results are obtained only when CTAD anti-coagulant is used. Using citrate UFH is underestimated in the absence of dextran sulfate. Heparin calibrators, adjustment of automation parameters and data treatment contribute to other smaller differences.
No takes yet. Share an insight, caveat, or question.
Amiral et al. (2021) conducted a review in Heparin therapy monitoring. Anti-FXa assays with dextran sulfate and CTAD anticoagulant vs. Assays without dextran sulfate or using citrate was evaluated on Heparin measurement accuracy. Anti-FXa assays incorporating low molecular weight dextran sulfate and utilizing CTAD anticoagulant optimize the accurate measurement of all in-vivo heparin activity.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: